Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.
Cabıoğlu N, Karanlık H, Yıldırım N, Müslümanoğlu M, Çakmak Karadeniz G, Trabulus Can D, Tükenmez M, Ersoy YE, Uras C, Zengel B, Emiroğlu S, Polat AK, Yeniay L, Özkurt E, Kara H, İbiş K, Aydıner A, Özmen V, İğci A. Cabıoğlu N, et al. Among authors: ibis k. Eur J Surg Oncol. 2021 Oct;47(10):2506-2514. doi: 10.1016/j.ejso.2021.06.024. Epub 2021 Jun 24. Eur J Surg Oncol. 2021. PMID: 34217580
Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients.
Dogan I, Aydin E, Khanmammadov N, Paksoy N, Ferhatoğlu F, Ak N, Emiroglu S, Ibis K, Onder S, Tukenmez M, Cabioglu N, Kucucuk S, Muslumanoğlu M, Ozmen V, Saip P, Igci A, Aydiner A. Dogan I, et al. Among authors: ibis k. J Cancer Res Clin Oncol. 2023 Nov;149(16):14833-14841. doi: 10.1007/s00432-023-05276-y. Epub 2023 Aug 18. J Cancer Res Clin Oncol. 2023. PMID: 37594533
Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided.
Muslumanoglu M, Cabioglu N, Igci A, Karanlık H, Kocer HB, Senol K, Mantoglu B, Tukenmez M, Çakmak GK, Ozkurt E, Gulcelik MA, Emiroglu S, Mollavelioglu B, Yildirim N, Bademler S, Zengel B, Trabulus DC, Ugurlu MU, Uras C, Ilgun S, Akgul GG, Akcan A, Yormaz S, Ersoy YE, Ozbas S, Dilege E, Citgez B, Bolukbasi Y, Altınok A, Dag A, Basaran G, Utkan NZ, Ozcinar B, Arici C, AlJorani I, Kara H, Yigit B, Sen E, Erozgen F, Soyder A, Celik B, Kilic HG, Zer L, Sakman G, Yeniay L, Atahan K, Varol E, Veliyeva V, Goktepe B, Velidedeoglu M, Karaman N, Soran A, Aydiner A, Yılmaz R, Ibis K, Ozmen V. Muslumanoglu M, et al. Among authors: ibis k. Cancer. 2025 Jan 1;131(1):e35610. doi: 10.1002/cncr.35610. Epub 2024 Oct 30. Cancer. 2025. PMID: 39476303 Free PMC article.
Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapy.
Muslumanoglu M, Mollavelioglu B, Cabioglu N, Emiroglu S, Tukenmez M, Karanlık H, Ozmen T, Yılmaz R, Comert RG, Onder S, Bayram A, Simsek DH, Oflas M, Ibis K, Aydıner A, Ozmen V, Igci A. Muslumanoglu M, et al. Among authors: ibis k. World J Surg Oncol. 2024 Oct 31;22(1):286. doi: 10.1186/s12957-024-03547-7. World J Surg Oncol. 2024. PMID: 39478502 Free PMC article.
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.
Cabioglu N, Karanlik H, Igci A, Muslumanoglu M, Gulcelik MA, Uras C, Kocer HB, Trabulus DC, Ozkurt E, Cakmak GK, Tukenmez M, Bademler S, Yildirim N, Akgul GG, Sen E, Senol K, Emiroglu S, Citgez B, Ersoy YE, Dag A, Zengel B, Basaran G, Kara H, Dilege E, Ugurlu MU, Celik A, Ilgun S, Bolukbasi Y, Karaman N, Sakman G, Ozbas S, Kilic HG, Polat AK, Ozemir IA, Kilic B, Altınok A, Varol E, Dogan L, Akcan A, Ozcinar B, Zer L, Soyder A, Velidedeoglu M, Erozgen F, Goktepe B, Dogan M, Kebudi A, Yigit B, Celik B, Yormaz S, Arici C, Agcaoglu O, Sevinc AI, Atahan MK, Valiyeva V, Baran E, Aljorani I, Utkan Z, Yeniay L, Kivilcim T, Soran A, Aydiner A, Ibis K, Ozmen V. Cabioglu N, et al. Among authors: ibis k. Ann Surg Oncol. 2025 Feb;32(2):952-966. doi: 10.1245/s10434-024-16472-6. Epub 2024 Dec 2. Ann Surg Oncol. 2025. PMID: 39623189
ASO Author Reflections: Nodal Recurrence Is Rare in Patients with cN+/ycN0 Breast Cancer after Neoadjuvant Chemotherapy Regardless of the Extent of Axillary Surgery or Nodal Pathology in the NEOSENTITURK-Trials MF18-02/18-03 Provided Regional Nodal Irradiation Is Administered.
Cabioglu N, Karanlik H, Igci A, Muslumanoglu M, Gulcelik MA, Uras C, Kocer HB, Soran A, Ibis K, Ozmen V. Cabioglu N, et al. Among authors: ibis k. Ann Surg Oncol. 2025 Feb;32(2):971-972. doi: 10.1245/s10434-024-16651-5. Epub 2024 Dec 9. Ann Surg Oncol. 2025. PMID: 39653946
De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer.
Cabioglu N, Koçer HB, Karanlik H, Gülçelik MA, Igci A, Müslümanoglu M, Uras C, Mantoglu B, Trabulus DC, Akgül G, Tükenmez M, Senol K, Özkurt E, Sen E, Karadeniz Çakmak G, Bademler S, Emiroglu S, Yildirim N, Kara H, Dag A, Dilege E, Altinok A, Basaran G, Varol E, Ugurlu Ü, Bölükbasi Y, Ersoy YE, Zengel B, Karaman N, Özbas S, Zer L, Gül Kiliç H, Agcaoglu O, Sakman G, Utkan Z, Soyder A, Akcan A, Ergün S, Yilmaz R, Aydiner A, Soran A, Ibis K, Özmen V. Cabioglu N, et al. Among authors: ibis k. JAMA Surg. 2025 Jan 2. doi: 10.1001/jamasurg.2024.5913. Online ahead of print. JAMA Surg. 2025. PMID: 39745737
36 results